Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-315: Subcutaneous versus intravenous tarlatamab in relapsed extensive-stage small cell lung cancer
jRCT2031260458Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Area under the curve from Cycle 2 Day 1 to Day 15 of tarlatamab and Predose concentration of tarlatamab. Started Aug 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031260458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260458.